Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipramine Pamoate

FDA-approved product (capsule, oral), marketed as Imipramine Hydrochloride, Janimine, Pramine and 4 more.

Registered studies
49
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Imipramine Pamoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Enuresis
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-selective monoamine reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imipramine Pamoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipramine Pamoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

    NCT07074756 · start 2025-09-12

    Registered record
    Registry ID
    NCT07074756
    Conditions
    Glioma; Recurrent Glioma; Recurrent Glioblastoma
    Interventions
    Chemotherapy; Computed Tomography; Internet-Based Intervention; Magnetic Resonance Imaging; Neurologic Examination; Questionnaire Administration; Surveillance; Propranolol; Imipramine; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-09-12
    Completion
    2028-08-31
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma; Recurrent Glioma; Recurrent Glioblastoma
    InterventionChemotherapy; Computed Tomography; Internet-Based Intervention; Magnetic Resonance Imaging +6 more
    PhaseNot applicable
    Registry statusRecruiting

  • The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

    NCT06778434 · start 2025-04-01

    Registered record
    Registry ID
    NCT06778434
    Conditions
    Actinic Keratosis; Imipramine; Photodynamic Therapy
    Interventions
    Imipramine; Control Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-01
    Completion
    2029-03-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis; Imipramine; Photodynamic Therapy
    InterventionImipramine; Control Vehicle
    PhasePhase 2
    Registry statusRecruiting

  • Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.

    NCT06778824 · start 2024-04-02

    Registered record
    Registry ID
    NCT06778824
    Conditions
    Gut-Brain Disorders; GERD Without Erosive Esophagitis
    Interventions
    Takepron; Zoloft 50Mg Tablet; Imipramine Pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-02
    Completion
    2026-12-31
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGut-Brain Disorders; GERD Without Erosive Esophagitis
    InterventionTakepron; Zoloft 50Mg Tablet; Imipramine Pill
    PhaseNot applicable
    Registry statusRecruiting

  • New Treatment for Nocturnal Enuresis in Children

    NCT06497647 · start 2024-03-01

    Registered record
    Registry ID
    NCT06497647
    Conditions
    Nocturnal Enuresis in Children
    Interventions
    Sulbutiamine; Imipramine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-03-01
    Completion
    2024-11
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturnal Enuresis in Children
    InterventionSulbutiamine; Imipramine
    PhaseNot applicable
    Registry statusUnknown

  • Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

    NCT06312813 · start 2024-02-27

    Registered record
    Registry ID
    NCT06312813
    Conditions
    Rosacea
    Interventions
    Imipramine; Amitriptyline; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-02-27
    Completion
    2028-12-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRosacea
    InterventionImipramine; Amitriptyline; Vehicle
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy of Hydroxyzine for Patients With Panic Disorder

    NCT05737511 · start 2023-12-30

    Registered record
    Registry ID
    NCT05737511
    Conditions
    Panic Disorder
    Interventions
    Hydroxyzine; Escitalopram Oxalate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2023-12-30
    Completion
    2026-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    InterventionHydroxyzine; Escitalopram Oxalate
    PhasePhase 4
    Registry statusNot yet recruiting

  • Therapeutic Efficacy in Women With Stress Urinary Incontinence

    NCT05677295 · start 2023-04-18

    Registered record
    Registry ID
    NCT05677295
    Conditions
    Women With Stress Urinary Incontinence
    Interventions
    duloxetine; Imipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-04-18
    Completion
    2024-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWomen With Stress Urinary Incontinence
    Interventionduloxetine; Imipramine
    PhasePhase 3
    Registry statusUnknown

  • The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

    NCT05688904 · start 2023-01-19

    Registered record
    Registry ID
    NCT05688904
    Conditions
    Imipramine; Photodynamic Therapy; Actinic Keratosis
    Interventions
    Imipramine; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-01-19
    Completion
    2028-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImipramine; Photodynamic Therapy; Actinic Keratosis
    InterventionImipramine; Vehicle
    PhasePhase 1
    Registry statusRecruiting

  • Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

    NCT05952713 · start 2022-10-01

    Registered record
    Registry ID
    NCT05952713
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-07-01
    Enrolment
    73,336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant
    PhaseNot recorded
    Registry statusCompleted

  • Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

    NCT04520217 · start 2022-06-06

    Registered record
    Registry ID
    NCT04520217
    Conditions
    Photosensitivity; Microvesicle Particle
    Interventions
    4% Imipramine Cream; Base Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-06-06
    Completion
    2026-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhotosensitivity; Microvesicle Particle
    Intervention4% Imipramine Cream; Base Cream
    PhasePhase 1
    Registry statusRecruiting

  • Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

    NCT04863950 · start 2022-05-25

    Registered record
    Registry ID
    NCT04863950
    Conditions
    Glioblastoma
    Interventions
    Lomustine; Imipramine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-05-25
    Completion
    2026-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionLomustine; Imipramine Hydrochloride
    PhasePhase 2
    Registry statusRecruiting

  • Bio-significance of LPC16:0 in Fibromyalgia

    NCT04832100 · start 2021-06-01

    Registered record
    Registry ID
    NCT04832100
    Conditions
    Fibromyalgia, Primary; Pain; Soreness, Muscle; Oxidative Stress; Metabolomics; Lipidomics
    Interventions
    Pregabalin 150mg, imipramine 25mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-06-01
    Completion
    2027-06-30
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia, Primary; Pain; Soreness, Muscle; Oxidative Stress +2 more
    InterventionPregabalin 150mg, imipramine 25mg
    PhaseNot recorded
    Registry statusRecruiting

  • Photodynamic Therapy and Microvesicles

    NCT03960125 · start 2021-03-29

    Registered record
    Registry ID
    NCT03960125
    Conditions
    Photodynamic Therapy; Microvesicle Particle
    Interventions
    Photodynamic Therapy; 4% Imipramine; Base Cream
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2021-03-29
    Completion
    2022-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhotodynamic Therapy; Microvesicle Particle
    InterventionPhotodynamic Therapy; 4% Imipramine; Base Cream
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Taste Supra-thresholds Among a Sample of Depressed Egyptian Adult Under Anti-depressants Therapy

    NCT04923321 · start 2021-02-22

    Registered record
    Registry ID
    NCT04923321
    Conditions
    Taste Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-02-22
    Completion
    2021-05-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaste Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study

    NCT04412876 · start 2020-05-31

    Registered record
    Registry ID
    NCT04412876
    Conditions
    Stress Urinary Incontinence
    Interventions
    Duloxetine; Imipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-05-31
    Completion
    2021-06-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Urinary Incontinence
    InterventionDuloxetine; Imipramine
    PhasePhase 3
    Registry statusWithdrawn